Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma
Growing evidence indicates that altered metabolism represents the hallmark of hepatocellular carcinoma (HCC). The mitochondrial 3-hydroxybutyrate dehydrogenase 1 (BDH1) is a key catalytic enzyme in ketogenesis with unknown roles in HCC. Hundred and four tissue sample pairs (HCC tissues, n = 104; mat...
Gespeichert in:
| Veröffentlicht in: | Pathology, research and practice research and practice, 2022-10, Vol.238, p.154111-154111, Article 154111 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 154111 |
|---|---|
| container_issue | |
| container_start_page | 154111 |
| container_title | Pathology, research and practice |
| container_volume | 238 |
| creator | Luo, Wenqi Wu, Shu Zhang, Fengyou Chen, Xiaoyu Ma, Yun Mo, Yingxi |
| description | Growing evidence indicates that altered metabolism represents the hallmark of hepatocellular carcinoma (HCC). The mitochondrial 3-hydroxybutyrate dehydrogenase 1 (BDH1) is a key catalytic enzyme in ketogenesis with unknown roles in HCC. Hundred and four tissue sample pairs (HCC tissues, n = 104; matched normal tissues, n = 104) were obtained and analyzed with immunohistochemical (IHC) staining to investigate the clinical and functional role and the diagnostic and prognostic value of BDH1 in HCC. In addition, RNA-Seq datasets from the Tumor Immune Estimation Resource (TIMER) (HCC group, n = 371; normal group, n = 50) and microarray datasets from the Gene Expression Omnibus (GEO) database (HCC tissues, n = 1671; normal tissues, n = 1479) were used to assess BDH1 expression in HCC. Several bioinformatic methods were performed to identify pathways regulated by BDH1. The IHC staining showed that BDH1 expression decreased in HCC tissues (n = 69) compared with that in adjacent normal tissues (n = 35, P |
| doi_str_mv | 10.1016/j.prp.2022.154111 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2715441424</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0344033822003557</els_id><sourcerecordid>2715441424</sourcerecordid><originalsourceid>FETCH-LOGICAL-c330t-4e4be21f95fb6466f908606b2782418358bdf92a86ed97089587dfa1d0c6d8713</originalsourceid><addsrcrecordid>eNp9kEFP3DAUhK2qlbql_IDefOwlWz_b6zjqCVHaIiFxgbPl2C_g7SYOtlOxv4E_jZeFK6cnjb4ZzRtCvgFbAwP1Y7ue07zmjPM1bCQAfCArUKAbpgR8JCsmpGyYEPoz-ZLzljHWMgkr8vQLXUKb0VN8nBPmHOJE40BFc7_3KT7u-6Xsky1IPb4odzhVnAINmVo6V2GKuQRHR5v-YaJ28gd1jAUzLcsY0wv0Fh0meo-zLdHhbrfsbKLOJhemONqv5NNgdxlPX-8Juf19cXP-t7m6_nN5fnbVOCFYaSTKHjkM3WbolVRq6JhWTPW81VyCFhvd-6HjViv0Xct0t9GtHyx45pTXLYgT8v2YW3s9LJiLGUM-1LETxiUb3tYJJUguKwpH1KWYc8LBzCnUR_cGmDkMb7ZVmc1heHMcvnp-Hj1Yf_gfMJnsAk4OfUjoivExvON-BsnRjmc</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2715441424</pqid></control><display><type>article</type><title>Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma</title><source>Elsevier ScienceDirect Journals</source><creator>Luo, Wenqi ; Wu, Shu ; Zhang, Fengyou ; Chen, Xiaoyu ; Ma, Yun ; Mo, Yingxi</creator><creatorcontrib>Luo, Wenqi ; Wu, Shu ; Zhang, Fengyou ; Chen, Xiaoyu ; Ma, Yun ; Mo, Yingxi</creatorcontrib><description>Growing evidence indicates that altered metabolism represents the hallmark of hepatocellular carcinoma (HCC). The mitochondrial 3-hydroxybutyrate dehydrogenase 1 (BDH1) is a key catalytic enzyme in ketogenesis with unknown roles in HCC. Hundred and four tissue sample pairs (HCC tissues, n = 104; matched normal tissues, n = 104) were obtained and analyzed with immunohistochemical (IHC) staining to investigate the clinical and functional role and the diagnostic and prognostic value of BDH1 in HCC. In addition, RNA-Seq datasets from the Tumor Immune Estimation Resource (TIMER) (HCC group, n = 371; normal group, n = 50) and microarray datasets from the Gene Expression Omnibus (GEO) database (HCC tissues, n = 1671; normal tissues, n = 1479) were used to assess BDH1 expression in HCC. Several bioinformatic methods were performed to identify pathways regulated by BDH1. The IHC staining showed that BDH1 expression decreased in HCC tissues (n = 69) compared with that in adjacent normal tissues (n = 35, P < 0.001). Low BDH1 expression was associated with advanced clinical stage (P = 0.033) and vascular invasion (P = 0.007). Moreover, ectopic expression of BDH1 reduced tumor proliferation and suppressed the migration and invasion of HCC cells in vitro. Therefore, our data suggest that BDH1 is a potentially valuable diagnostic biomarker and therapeutic target for HCC.</description><identifier>ISSN: 0344-0338</identifier><identifier>EISSN: 1618-0631</identifier><identifier>DOI: 10.1016/j.prp.2022.154111</identifier><language>eng</language><publisher>Elsevier GmbH</publisher><subject>BDH1 ; Hepatocellular carcinoma ; Immunohistochemistry ; Prognostic marker ; Tumor suppressor</subject><ispartof>Pathology, research and practice, 2022-10, Vol.238, p.154111-154111, Article 154111</ispartof><rights>2022 The Authors</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c330t-4e4be21f95fb6466f908606b2782418358bdf92a86ed97089587dfa1d0c6d8713</citedby><cites>FETCH-LOGICAL-c330t-4e4be21f95fb6466f908606b2782418358bdf92a86ed97089587dfa1d0c6d8713</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0344033822003557$$EHTML$$P50$$Gelsevier$$Hfree_for_read</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids></links><search><creatorcontrib>Luo, Wenqi</creatorcontrib><creatorcontrib>Wu, Shu</creatorcontrib><creatorcontrib>Zhang, Fengyou</creatorcontrib><creatorcontrib>Chen, Xiaoyu</creatorcontrib><creatorcontrib>Ma, Yun</creatorcontrib><creatorcontrib>Mo, Yingxi</creatorcontrib><title>Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma</title><title>Pathology, research and practice</title><description>Growing evidence indicates that altered metabolism represents the hallmark of hepatocellular carcinoma (HCC). The mitochondrial 3-hydroxybutyrate dehydrogenase 1 (BDH1) is a key catalytic enzyme in ketogenesis with unknown roles in HCC. Hundred and four tissue sample pairs (HCC tissues, n = 104; matched normal tissues, n = 104) were obtained and analyzed with immunohistochemical (IHC) staining to investigate the clinical and functional role and the diagnostic and prognostic value of BDH1 in HCC. In addition, RNA-Seq datasets from the Tumor Immune Estimation Resource (TIMER) (HCC group, n = 371; normal group, n = 50) and microarray datasets from the Gene Expression Omnibus (GEO) database (HCC tissues, n = 1671; normal tissues, n = 1479) were used to assess BDH1 expression in HCC. Several bioinformatic methods were performed to identify pathways regulated by BDH1. The IHC staining showed that BDH1 expression decreased in HCC tissues (n = 69) compared with that in adjacent normal tissues (n = 35, P < 0.001). Low BDH1 expression was associated with advanced clinical stage (P = 0.033) and vascular invasion (P = 0.007). Moreover, ectopic expression of BDH1 reduced tumor proliferation and suppressed the migration and invasion of HCC cells in vitro. Therefore, our data suggest that BDH1 is a potentially valuable diagnostic biomarker and therapeutic target for HCC.</description><subject>BDH1</subject><subject>Hepatocellular carcinoma</subject><subject>Immunohistochemistry</subject><subject>Prognostic marker</subject><subject>Tumor suppressor</subject><issn>0344-0338</issn><issn>1618-0631</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kEFP3DAUhK2qlbql_IDefOwlWz_b6zjqCVHaIiFxgbPl2C_g7SYOtlOxv4E_jZeFK6cnjb4ZzRtCvgFbAwP1Y7ue07zmjPM1bCQAfCArUKAbpgR8JCsmpGyYEPoz-ZLzljHWMgkr8vQLXUKb0VN8nBPmHOJE40BFc7_3KT7u-6Xsky1IPb4odzhVnAINmVo6V2GKuQRHR5v-YaJ28gd1jAUzLcsY0wv0Fh0meo-zLdHhbrfsbKLOJhemONqv5NNgdxlPX-8Juf19cXP-t7m6_nN5fnbVOCFYaSTKHjkM3WbolVRq6JhWTPW81VyCFhvd-6HjViv0Xct0t9GtHyx45pTXLYgT8v2YW3s9LJiLGUM-1LETxiUb3tYJJUguKwpH1KWYc8LBzCnUR_cGmDkMb7ZVmc1heHMcvnp-Hj1Yf_gfMJnsAk4OfUjoivExvON-BsnRjmc</recordid><startdate>202210</startdate><enddate>202210</enddate><creator>Luo, Wenqi</creator><creator>Wu, Shu</creator><creator>Zhang, Fengyou</creator><creator>Chen, Xiaoyu</creator><creator>Ma, Yun</creator><creator>Mo, Yingxi</creator><general>Elsevier GmbH</general><scope>6I.</scope><scope>AAFTH</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>202210</creationdate><title>Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma</title><author>Luo, Wenqi ; Wu, Shu ; Zhang, Fengyou ; Chen, Xiaoyu ; Ma, Yun ; Mo, Yingxi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c330t-4e4be21f95fb6466f908606b2782418358bdf92a86ed97089587dfa1d0c6d8713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>BDH1</topic><topic>Hepatocellular carcinoma</topic><topic>Immunohistochemistry</topic><topic>Prognostic marker</topic><topic>Tumor suppressor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Luo, Wenqi</creatorcontrib><creatorcontrib>Wu, Shu</creatorcontrib><creatorcontrib>Zhang, Fengyou</creatorcontrib><creatorcontrib>Chen, Xiaoyu</creatorcontrib><creatorcontrib>Ma, Yun</creatorcontrib><creatorcontrib>Mo, Yingxi</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pathology, research and practice</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Luo, Wenqi</au><au>Wu, Shu</au><au>Zhang, Fengyou</au><au>Chen, Xiaoyu</au><au>Ma, Yun</au><au>Mo, Yingxi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma</atitle><jtitle>Pathology, research and practice</jtitle><date>2022-10</date><risdate>2022</risdate><volume>238</volume><spage>154111</spage><epage>154111</epage><pages>154111-154111</pages><artnum>154111</artnum><issn>0344-0338</issn><eissn>1618-0631</eissn><abstract>Growing evidence indicates that altered metabolism represents the hallmark of hepatocellular carcinoma (HCC). The mitochondrial 3-hydroxybutyrate dehydrogenase 1 (BDH1) is a key catalytic enzyme in ketogenesis with unknown roles in HCC. Hundred and four tissue sample pairs (HCC tissues, n = 104; matched normal tissues, n = 104) were obtained and analyzed with immunohistochemical (IHC) staining to investigate the clinical and functional role and the diagnostic and prognostic value of BDH1 in HCC. In addition, RNA-Seq datasets from the Tumor Immune Estimation Resource (TIMER) (HCC group, n = 371; normal group, n = 50) and microarray datasets from the Gene Expression Omnibus (GEO) database (HCC tissues, n = 1671; normal tissues, n = 1479) were used to assess BDH1 expression in HCC. Several bioinformatic methods were performed to identify pathways regulated by BDH1. The IHC staining showed that BDH1 expression decreased in HCC tissues (n = 69) compared with that in adjacent normal tissues (n = 35, P < 0.001). Low BDH1 expression was associated with advanced clinical stage (P = 0.033) and vascular invasion (P = 0.007). Moreover, ectopic expression of BDH1 reduced tumor proliferation and suppressed the migration and invasion of HCC cells in vitro. Therefore, our data suggest that BDH1 is a potentially valuable diagnostic biomarker and therapeutic target for HCC.</abstract><pub>Elsevier GmbH</pub><doi>10.1016/j.prp.2022.154111</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-0338 |
| ispartof | Pathology, research and practice, 2022-10, Vol.238, p.154111-154111, Article 154111 |
| issn | 0344-0338 1618-0631 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2715441424 |
| source | Elsevier ScienceDirect Journals |
| subjects | BDH1 Hepatocellular carcinoma Immunohistochemistry Prognostic marker Tumor suppressor |
| title | Decreased expression of 3-hydroxybutyrate dehydrogenase 1 is a prognostic marker and promotes tumor progression in hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T01%3A11%3A05IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Decreased%20expression%20of%203-hydroxybutyrate%20dehydrogenase%201%20is%20a%20prognostic%20marker%20and%20promotes%20tumor%20progression%20in%20hepatocellular%20carcinoma&rft.jtitle=Pathology,%20research%20and%20practice&rft.au=Luo,%20Wenqi&rft.date=2022-10&rft.volume=238&rft.spage=154111&rft.epage=154111&rft.pages=154111-154111&rft.artnum=154111&rft.issn=0344-0338&rft.eissn=1618-0631&rft_id=info:doi/10.1016/j.prp.2022.154111&rft_dat=%3Cproquest_cross%3E2715441424%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2715441424&rft_id=info:pmid/&rft_els_id=S0344033822003557&rfr_iscdi=true |